In a stock market that favors the giants, it's still possible to reap big gains investing in Wall Street's small fries. The post How This Top Small-Cap Growth Fund Wins Big appeared first on Investor's Business Daily.
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference Call on Monday, March 3rd, 2025. At this time, all participants are in a listen-only mode.
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
ADMA Biologics' shares lose 8.9% in a month after putting up a phenomenal performance in the past 12 months. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.
ADMA Biologics specializes in primary immune deficiencies with Asceniv, a high-margin, unique product that outperforms competitors and has significant growth potential in the U.S. market. Asceniv's high-titer plasma offers superior protection with minimal side effects, positioning it as a leading second-line treatment for severe PI patients. ADMA's strategic plasma collection expansion and patented methods ensure a reliable supply, supporting future growth and high-margin revenue projections exceeding $1 billion by 2030.
Adma Biologics (ADMA) concluded the recent trading session at $16.47, signifying a +1.98% move from its prior day's close.
Adma Biologics (ADMA) closed the most recent trading day at $16.17, moving -0.12% from the previous trading session.
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
The major tech stocks known as the Magnificent Seven, along with leading AI companies, contributed to significant growth in many large-cap mutual funds. One of the top funds achieved a return of 51.8%.
ADMA Biologics performance in the past twelve months has been phenomenal. While the prospects remain sound, the exceptional rally witnessed by the stock might limit any further gain.